Potential non-invasive biomarkers in tumor immune checkpoint inhibitor therapy: response and prognosis prediction

Immune checkpoint inhibitors (ICIs) have dramatically enhanced the treatment outcomes for diverse malignancies. Yet, only 15–60% of patients respond significantly. Therefore, accurate responder identification and timely ICI administration are critical issues in tumor ICI therapy. Recent rapid develo...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Ruixia, Liu, Fengsen, Ping, Yu, Zhang, Yi, Wang, Liping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236604/
https://www.ncbi.nlm.nih.gov/pubmed/37268978
http://dx.doi.org/10.1186/s40364-023-00498-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236604/
https://www.ncbi.nlm.nih.gov/pubmed/37268978
http://dx.doi.org/10.1186/s40364-023-00498-1

Ejemplares similares